Bill Booth kindly invited me on to his podcast to discuss health and medicine. Bill is one of the founders of Radical Americas, an academic network for scholars and activists with interests in radicalism in the Western Hemisphere.
The ADHS is pleased to announce that the editorship of its journal, *The Social History of Alcohol and Drugs*, will be taken over by Prof. Nancy D. Campbell (Rensselaer Polytechnic Institute), Prof. David Herzberg (Buffalo) and Dr. Lucas Richert (Strathclyde). The society would also like to express its gratitude for the work that outgoing editor, […]
The ADHS is excited to announce that its next bi-annual conference will be held between 12 and 15 June 2019, at the David F. Musto Center for Drug Policy Studies, Shanghai University, China. The conference will be organised by Prof. Jim Mills, of the University of Strathclyde and Prof. Yong-an Zhang of Shanghai University, who […]
Here is a snapshot of the past week in Big Pharma news. This is coming at you a little early because of the Christmas slowdown. Happy holidays.
To kick off:
The drug industry spent big!
Here’s another one on the lobbying money spent over the past months and years…
A lot of money was splashed out. ‘“Does that surprise you?” said Billy Tauzin, the former PhRMA CEO who ran the organization a decade ago as Obamacare loomed. Whenever Washington seems interested in limiting drug prices, he said, “PhRMA has always responded by increasing its resources.”’
In Canada, there’s efforts to reduce “sticker shock” when purchasing drugs.
“A Toronto family doctor thinks she has a prescription for the nasty surprise many patients experience when they go to the pharmacy and learn just how much their medications will cost.”
What about other countries besides the US? Say, Poland. It spends a lot on pharmaceuticals – but on the right drugs?
Then, more on opioids. Ravaged by Opioids!
Away from the young, and to the old: could drugs slow ageing?
“Some pharmaceutical companies are exploring whether [certain] genetic traits could be used to create anti-ageing drugs.”
And in BC, Canada: illicit placenta and stem cell therapies were seized!!!
‘The drugs confiscated from Before & After Beauty Lab on Hazelbridge Way “may pose serious risks to health,” according to a Health Canada press release.’
There was a also mysterious double murder in the world of Big Pharma!
Here at Strathclyde, CMAC welcomes Pfizer as newest partner…
“CMAC (Continuous Manufacturing and Advanced Crystallisation), a pre-competitive consortium led by the University of Strathclyde to accelerate progress in pharmaceutical manufacturing, announces that Pfizer Inc has joined as a strategic member, alongside GSK, AZ, Novartis, Bayer, Takeda, Lilly and Roche.”
Lastly, St Thomas University (Canada) is hiring a cannabis/marijuana scholar. As the cannabis industry consolidates and the medicine is refined further, the job is a useful chance to contribute to the discussion. And it looks spectacular.
Here is a flyer for my book on Big Pharma! Cheap, cheap, cheap.
A round up of the recent Big Pharma and FDA stories.
Antibiotics in Farm Animals Drop:
Teva Pharmaceuticals is being reshaped:
Rebooting the FDA:
Top 5 Stories of 2017:
FDA clears the Apple watch:
The FDA is going to go after price gouging:
And supplement makers:
Bipartisanship on Drug Prices:
I’ve more than likely missed some angles and stories. Drop me a line if you have suggestions.
Here’s a flyer for 30% off my Big Pharma book!
FROM THE CBC:
It was probably one of the most bizarre medical cases a team of Italian doctors had ever seen.
A 21-year-old woman was admitted to hospital with a condition that caused her to sweat blood from her face and from the palms of her hands. This despite any sign of skin lesions.
The case was highlighted Monday in the Canadian Medical Association Journal (CMAJ).
Doctors say the patient had a three-year history of bleeding. There was no obvious trigger, and the spontaneous bleeding could happen while she slept and during physical activity. More intense bleeding happened when the patient was under stress, with episodes lasting anywhere between one and five minutes.
Canadian medical historian Jacalyn Duffin says at first she was skeptical whether people could sweat blood. She thought the Italian doctors were being duped. But after an exhaustive review of historical literature and more recent reports on cases of hematohidrosis, or sweating blood, she’s a believer.
“After all the research that I’ve done, I am convinced of the plausibility and the possibility that it exists,” she said. Duffin, who is also a hematologist, wrote a commentary that accompanies the journal article.
She acknowledges that hematohidrosis syndrome is incredibly rare. The medical history has been “muddled” with references in religious literature to the crucifixion of Christ, she says and the two are very difficult to separate.
“But case reports start appearing in the 16th century, and quite distinct from anything to do with the crucifixion, or Christianity”, she says. “There are mentions of the phenomenon as far back as Aristotle … prior to the time of Jesus,” she told CBC News from her home in Kingston, Ont.
Read the full article here.
Following party conferences, it seemed worthwhile to raise the issue of disability politics and the welfare state. The topic is tackled by Dr Jameel Hampton. As he describes it: “Created during and after the Second World War, the British Welfare State seemed to promise welfare for all, but, in its original form, excluded millions of disabled people.”
His recent book examines attempts “to reverse this exclusion.” Considering the recent emergence of the history of disability in Britain as a major area of research, the book can add to the conversation.
According to C Norris, in Oxford University Press’ This Year’s Work in Critical and Cultural Theory, “Disability and the Welfare State in Britain is a remarkable achievement. Hampton’s excavation and elucidation of archival material related to the Disability Income Group, as well as other key players in the debates over disability and statutory welfare in Britain in the twentieth century, is both important and impressive.”
* Dr Jameel Hampton teaches at Liverpool Hope University (firstname.lastname@example.org)
Some doctors are struggling with allowing Canadians to die on their own terms.
Here I share a powerful article by Krista Stevens.
It’s my pleasure to promote the publication of an important Policy Brief on Cannabis by Kathleen Thompson. Over the past few years she has helped drive conversations about the consumption and control of marijuana. Her recent Policy Brief ought to be read by anyone and everyone! Here’s an extract.
LEGALIZATION OF CANNABIS: THE POLICY CHALLENGES AND OPPORTUNITIES
By Kathleen Thompson, PhD, MSW, RSW, BA (Hons)
“The commitment by the Government of Canada to legalize cannabis
and cannabis products presents a complex range of socio-economic
challenges and opportunities. Creating the right legal and regulatory
framework to address the implications, both good and bad, will be
key in determining whether legalization is deemed successful public
The federal government plans to introduce cannabis legislation in the
coming spring session of Parliament. The legislation will be based on
the recommendations contained in a report issued on November 30 by
a Task Force of experts who studied the issue for the past year. The Task
Force received input from more than 30,000 Canadians, organizations
and professionals. Entitled “A Framework for the Legalization and
Regulation of Cannabis in Canada”, the report recommends allowing
more flexibility in the current federally controlled cannabis cultivation
model. Specifically, the federal government would regulate a safe and
responsible supply chain of cannabis.”
ABOUT KATHLEEN THOMPSON
Dr. Thompson has worked in health policy analysis and research as a bureaucrat and as a consultant for the last 25 years, specializing in the mental health, disability and corrections sectors.
In 2015, Dr. Thompson created the Cannabis Regulatory Research Group. The focus of the policy research group is on promoting collaborative public policy processes and evidenced-based research with the cannabis industry, governments, academia, civil society and at the United Nations. Additionally, Dr. Thompson consults with individuals and organizations on how to enter the legal cannabis industry.